Operating Data

Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO)

$7.6
-0.27 (-3.43%)

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Projected
2021
Projected
2022
Projected
2023
Projected
Revenue 36.4314.6623.0732.4236.5541.1946.4352.34
Revenue (%)
EBITDA -123.58-50.82-49.27-40.36-93.56-105.46-118.88-134.00
EBITDA (%)
EBIT -126.95-53.95-51.66-42.60-97.93-110.39-124.43-140.25
EBIT (%)
Depreciation 3.363.132.392.234.374.925.556.25
Depreciation (%)




EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT)
EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income)
EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization
EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company
(1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments),
(2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill)
(3*) collections of assets (by ignoring depreciation of assets)
(4*) different takeover histories (by ignoring amortization often stemming from goodwill)